Department of Error

Chan WY, Pires da Silva I, Long GV, Rizos H. Targeting MEK in cancer and beyond: mechanistic insights and therapeutic opportunities. Lancet 2026; 407: 1639–56—In this Therapeutics paper, in table 2, the objective response rate (95% CI) should have been 15% (11–20) for the binimetinib group in the NEMO trial and 64% (59–69) for the trametinib + dabrafenib group in the Combi-v trial. The median progression-free survival (95% CI) in the NEMO trial should have been 2·8 months (2·8–3·6) in the binimetinib group and 1·5 (1·5–1·7) in the dacarbazine group. The number of patients in the IMspire150 trial should have been 255 in the cobimetinib + vemurafenib + atezolizumab group and 246 in the cobimetinib + vemurafenib + placebo group. These corrections have been made to the online version as of Oct 1, 2026. © 2026 Elsevier Ltd.